DAX25.123 +1,1%Est506.092 +0,9%MSCI World4.343 -0,1%Top 10 Crypto8,5600 +0,1%Nas23.066 -0,2%Bitcoin56.421 ±0,0%Euro1,1878 ±0,0%Öl69,68 +0,1%Gold5.064 -0,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Siemens Energy ENER6Y Gerresheimer A0LD6E SAP 716460 Rheinmetall 703000 Deutsche Telekom 555750 NVIDIA 918422 BASF BASF11 Lufthansa 823212 Commerzbank CBK100 Amazon 906866 Allianz 840400 Microsoft 870747 Mercedes-Benz Group (ex Daimler) 710000 DroneShield A2DMAA Bayer BAY001
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX im Plus -- Asiens Börsen uneins -- Mercedes-Benz mit Gewinneinbruch -- Siemens erhöht Ergebnisprognose -- Deutsche Börse, Novo Nordisk, Viking, Lufthansa, thyssenkrupp, Cisco im Fokus
Top News
Deutsche Börse-Aktie fester: Rekordzahlen für 2025 gemeldet - Milliardensumme für ISS Stoxx-Übernahme Deutsche Börse-Aktie fester: Rekordzahlen für 2025 gemeldet - Milliardensumme für ISS Stoxx-Übernahme
Lufthansa-Aktie gewinnt trotzdem: Streik und Warnstreik haben begonnen Lufthansa-Aktie gewinnt trotzdem: Streik und Warnstreik haben begonnen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

CSL Aktie

Kaufen
Verkaufen
CSL Aktien-Sparplan
91,41 EUR -4,28 EUR -4,47 %
STU
83,51 CHF -5,38 CHF -6,06 %
BRX
CSL jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.49,86 Mrd. EUR

KGV25,01Div. Rendite1,89%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN890952

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINAU000000CSL8

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolCMXHF

CSL Aktien News

DatumMeistgelesen
PR NewswireCSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older
PR NewswireCSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
PR NewswireCSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older
PR NewswireCSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older
PR NewswireCSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance
PR NewswireCSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in Peopl...
PR NewswireJapan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
PR NewswireIron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
PR NewswireIron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
PR NewswireIron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
PR NewswireIron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
PR NewswireCSL and uniQure Win 2023 Prix Galien USA Award
PR NewswireHealth Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B
PR NewswireCSL Signs Renewable-Linked Power Purchase Agreement with AGL to Supply Electricity to Australian Manufacturing Sites
PR NewswireNew Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines
PR NewswireCSL Seqirus Presents Real-World Evidence at ESWI Demonstrating the Impact of Influenza Vaccination Campaigns to Help Protect People and Healthcare Systems
PR NewswireCSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources
PR NewswireCSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine
PR NewswireFerinject® granted upgraded recommendations in 2023 ESC heart failure guidelines
PR NewswireFerinject® granted upgraded recommendations in 2023 ESC heart failure guidelines
PR NewswireFerinject® granted upgraded recommendations in 2023 ESC heart failure guidelines
PR NewswireFerinject® granted upgraded recommendations in 2023 ESC heart failure guidelines
PR NewswireFerinject® granted upgraded recommendations in 2023 ESC heart failure guidelines
PR NewswireCSL ernennt Jeffrey Ball zum ersten Chief Sustainability Officer
PR NewswireCSL Appoints Jeffrey Ball as First Chief Sustainability Officer
Dow JonesMÄRKTE ASIEN/Börsen in China von mauer Konjunktur gebremst - Tokio erholt
PR NewswireCSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2023/24 U.S. Season
PR NewswireCSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B
Dow JonesMÄRKTE ASIEN/Tokio erneut Tagessieger - Warten auf Fed
PR NewswireInjectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure
PR NewswireInjectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure
PR NewswireInjectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure
PR NewswireInjectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure
PR NewswireInjectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure
PR NewswireKapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
PR NewswireKapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
PR NewswireKapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
PR NewswireKapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
PR NewswireKapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
PR NewswireTopline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

CSL News

CSL News: auf dieser Seite finden Sie alle CSL News und Nachrichten zur CSL Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch CSL News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um CSL News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.